PubRank

M van Ballegooijen

Author PubWeight™ 57.41‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007 5.81
2 Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010 4.59
3 Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 2000 3.92
4 A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999 2.32
5 PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996 2.13
6 Predicting mortality from cervical cancer after negative smear test results. BMJ 1992 2.01
7 Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol 2012 1.98
8 The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res 1999 1.98
9 Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009 1.93
10 Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG 2012 1.57
11 A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 1998 1.49
12 Endocervical status is not predictive of the incidence of cervical cancer in the years after negative smears. Am J Clin Pathol 2001 1.45
13 The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy 2012 1.44
14 Economic aspects of cervical cancer screening. Soc Sci Med 1990 1.34
15 Colorectal cancer risk in adenoma patients: a nation-wide study. Int J Cancer 2004 1.15
16 [The 1996 revision of the Dutch cervical cancer screening programme: increased coverage, fewer repeat smears and less opportunistic screening]. Ned Tijdschr Geneeskd 2007 1.09
17 Women who participate in spontaneous screening are not at higher risk for cervical cancer than women who attend programme screening. Eur J Cancer 2002 1.08
18 A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br J Cancer 2000 1.08
19 [Less pap-2 results ('minor abnormalities') in the population screening for cervical cancer since the introduction of new guidelines in 1996]. Ned Tijdschr Geneeskd 2002 1.07
20 Cervical-cancer screening: attendance and cost-effectiveness. Int J Cancer 1990 1.06
21 Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer 2010 1.05
22 Non-progression of cervical intraepithelial neoplasia estimated from population-screening data. Br J Cancer 1997 1.00
23 What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy? Eur J Cancer 2013 0.99
24 Predictors of HPV vaccination uptake: a longitudinal study among parents. Health Educ Res 2013 0.99
25 Colorectal cancer risk after colonoscopic polypectomy: a population-based study and literature search. Eur J Cancer 2005 0.94
26 Low risk of cervical cancer during a long period after negative screening in the Netherlands. Br J Cancer 2003 0.93
27 Advance notification letters increase adherence in colorectal cancer screening: a population-based randomized trial. Prev Med 2011 0.92
28 Population screening for colorectal cancer: faeces, endoscopes or X-rays? Cell Oncol 2007 0.90
29 Report on the Dutch consensus development meeting for implementation and further development of population screening for colorectal cancer based on FOBT. Cell Oncol 2005 0.84
30 The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening. Br J Cancer 2009 0.83
31 Risk factors for false positive and for false negative test results in screening with fecal occult blood testing. Int J Cancer 2013 0.83
32 Having a Pap smear, quality of life before and after cervical screening: a questionnaire study. BJOG 2012 0.81
33 Quality of life in participants of a CRC screening program. Br J Cancer 2012 0.81
34 Unit costs in population-based colorectal cancer screening using CT colonography performed in university hospitals in The Netherlands. Eur Radiol 2012 0.79
35 Extended duration of the detectable stage by adding HPV test in cervical cancer screening. Br J Cancer 2003 0.77
36 Organised cervical cancer screening still leads to higher coverage than spontaneous screening in The Netherlands. Eur J Cancer 1998 0.77
37 Cost analysis of PAPNET-assisted vs. conventional Pap smear evaluation in primary screening of cervical smears. Acta Cytol 2001 0.76
38 Time requirements and health effects of participation in colorectal cancer screening with colonoscopy or computed tomography colonography in a randomized controlled trial. Endoscopy 2013 0.76
39 Impact of systematic false-negative test results on the performance of faecal occult blood screening. Eur J Cancer 2001 0.75
40 Is PAPNET suitable for primary screening? Lancet 1999 0.75
41 Withdrawing low risk women from cervical screening programmes. Conclusions cannot yet be drawn. BMJ 1999 0.75
42 [Possible effectiveness of mass screening of the population for cervical cancer]. Ned Tijdschr Geneeskd 1997 0.75
43 Positive diagnostic values and histological detection ratios from the Rotterdam cervical cancer screening programme. Int J Epidemiol 1998 0.75
44 Screening for colorectal cancer: which test can we afford? Z Gastroenterol 2008 0.75